Onyx Pharmaceuticals, Inc.

James R Bischoff

Maria Jose Fernandez-Sarabia

David H Kirn

Julie Nye

Angelica Williams

Sharon Horn

Lelia Ng

Lelia Wu

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of

The invention provides mammalian polypeptides which bind wild-type and/or mutant mamalian p53 proteins, polynucleotides encoding such polypeptides, screening assays for drug development employing such polypeptides and polynucleotides, immunological and other reagents for diagnostic, therapeutic, and research applications.

P53-binding polypeptides and polynucleotides encoding same

The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantially pure protein complex comprising a R-ras polypeptide and a bcl-2 polypeptide.

Interaction of BCL-2 and R-RAS

Bcl-2 and R-ras complex

Growing community of inventors

Kensington, CA, United States of America

James R Bischoff